Fig. 9.

Example of uPAR liposomal targeting in breast cancer. Biodistribution and pharmacokinetics of the radiolabeled N-alkylisatin-loaded liposomes (N-AI) and plasminogen activator inhibitor-2 (PAI-2)-functionalized N-alkylisatin-loaded liposomes (N-AI PAI-2) over time. Measurements were taken in the plasma, primary tumor, kidneys, liver, spleen, and lungs of mice after one intravenous bolus injection. Note that 0.5% of the dose of PAI-2-functionalized liposomes was observed in the primary tumor soon after injection. Adapted from Ref. [154].